Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Organ preservation for adenoid cystic carcinoma of the larynx.
Misiukiewicz KJ, Camille N, Tishler R, Haddad R, Limaye S, Posner M. Misiukiewicz KJ, et al. Among authors: limaye s. Oncologist. 2013;18(5):579-83. doi: 10.1634/theoncologist.2012-0349. Epub 2013 Apr 24. Oncologist. 2013. PMID: 23615699 Free PMC article.
Trastuzumab for the treatment of salivary duct carcinoma.
Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI. Limaye SA, et al. Oncologist. 2013;18(3):294-300. doi: 10.1634/theoncologist.2012-0369. Epub 2013 Feb 21. Oncologist. 2013. PMID: 23429737 Free PMC article.
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Haddad R, et al. Among authors: limaye s. Lancet Oncol. 2013 Mar;14(3):257-64. doi: 10.1016/S1470-2045(13)70011-1. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414589 Clinical Trial.
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Hanna GJ, et al. Among authors: limaye sa. Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4. Clin Cancer Res. 2018. PMID: 29301825 Clinical Trial.
Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy.
Limaye SA, Haddad RI, Cilli F, Sonis ST, Colevas AD, Brennan MT, Hu KS, Murphy BA. Limaye SA, et al. Cancer. 2013 Dec 15;119(24):4268-76. doi: 10.1002/cncr.28365. Epub 2013 Sep 24. Cancer. 2013. PMID: 24114811 Free article. Clinical Trial.
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K. Bauml JM, et al. Among authors: limaye s. J Natl Cancer Inst. 2019 May 1;111(5):490-497. doi: 10.1093/jnci/djy133. J Natl Cancer Inst. 2019. PMID: 30239887 Free PMC article.
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.
Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K. Bauml JM, et al. Among authors: limaye s. Cancer. 2019 Feb 1;125(3):406-415. doi: 10.1002/cncr.31816. Epub 2018 Oct 20. Cancer. 2019. PMID: 30341983 Free PMC article.
192 results